Enzon Pharmaceuticals Inc (ENZN)
0.0755
0.00 (0.00%)
USD |
OTCM |
Nov 14, 15:28
Enzon Pharmaceuticals Enterprise Value: -40.73M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -40.73M |
| November 12, 2024 | -40.77M |
| November 11, 2024 | -40.35M |
| November 08, 2024 | -40.32M |
| November 07, 2024 | -40.32M |
| November 06, 2024 | -40.32M |
| November 05, 2024 | -39.97M |
| November 04, 2024 | -40.79M |
| November 01, 2024 | -40.51M |
| October 31, 2024 | -39.95M |
| October 30, 2024 | -40.92M |
| October 29, 2024 | -39.95M |
| October 28, 2024 | -40.70M |
| October 25, 2024 | -39.20M |
| October 24, 2024 | -38.84M |
| October 23, 2024 | -38.84M |
| October 22, 2024 | -38.54M |
| October 21, 2024 | -37.36M |
| October 18, 2024 | -37.36M |
| October 17, 2024 | -37.93M |
| October 16, 2024 | -37.93M |
| October 15, 2024 | -37.93M |
| October 14, 2024 | -38.47M |
| October 11, 2024 | -38.03M |
| October 10, 2024 | -38.46M |
| Date | Value |
|---|---|
| October 09, 2024 | -37.99M |
| October 08, 2024 | -38.46M |
| October 07, 2024 | -37.01M |
| October 04, 2024 | -38.47M |
| October 03, 2024 | -36.26M |
| October 02, 2024 | -38.10M |
| October 01, 2024 | -37.74M |
| September 30, 2024 | -36.24M |
| September 27, 2024 | -37.32M |
| September 26, 2024 | -37.25M |
| September 25, 2024 | -37.25M |
| September 24, 2024 | -35.20M |
| September 23, 2024 | -37.17M |
| September 20, 2024 | -35.78M |
| September 19, 2024 | -35.78M |
| September 18, 2024 | -36.41M |
| September 17, 2024 | -36.21M |
| September 16, 2024 | -37.32M |
| September 13, 2024 | -36.87M |
| September 12, 2024 | -36.84M |
| September 11, 2024 | -36.94M |
| September 10, 2024 | -36.37M |
| September 09, 2024 | -35.84M |
| September 06, 2024 | -35.10M |
| September 05, 2024 | -34.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-42.56M
Minimum
Mar 19 2024
15.47M
Maximum
Dec 29 2020
-19.52M
Average
-24.44M
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 7.900M |
| Perspective Therapeutics Inc | 378.39M |
| Protalix BioTherapeutics Inc | 66.58M |
| Electromed Inc | 224.00M |
| Armata Pharmaceuticals Inc | 183.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.254M |
| Total Expenses (Quarterly) | 0.351M |
| EPS Diluted (Quarterly) | -0.0037 |
| Earnings Yield | 1.73% |
| Normalized Earnings Yield | 2.928 |